Kazia Therapeutics (KZIA) Interest Expenses (2009 - 2017)

Kazia Therapeutics' (KZIA) quarterly Interest Expenses came in at $506552.8 in Q2 2010, up 236.91% on a QoQ basis from -$370000.0 in Q4 2009.

Kazia Therapeutics (KZIA) Interest Expenses (2009 - 2017) Analysis & Trends

Kazia Therapeutics (KZIA) has 2 years of Interest Expenses data on file, last reported at $506552.8 in Q2 2010.

Quarterly Interest Expenses changed N/A year-over-year to $506552.8 in Q2 2010, while the trailing twelve-month figure through Dec 2011 was $506552.8 (up 270.96% YoY) and the FY2017 annual result came in at $576858.1, changed N/A from the prior year.
Interest Expenses improved to $506552.8 in Q2 2010, from -$370000.0 in the prior quarter.
In the past five years, Interest Expenses ranged from a high of $506552.8 in Q2 2010 to a low of -$370000.0 in Q4 2009.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Int Expense (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	439.40 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	52.50 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	2.70 Bn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	39.74 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	335,572.77
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	218.10 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	82.05 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	20.27 Mn
10	Kazia Therapeutics	4.22 Bn	4.22 Bn	-	-

Download Data